London/New York, 21 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it had formally...
News Media & Publications
Scheme Effective Date
London/New York, 20 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it had formally...
PDMR Dealing
London, New York, 20 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been...
Court Sanctions the Scheme of Arrangement and approves Reduction of Capital
London/New York, 19 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it had formally...
PDMR Dealing
London, New York, 6 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been...
PDMR Dealing
London, New York, 5 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been...
PDMR Dealing
London, New York, 4 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been...
PDMR Dealing
London, New York, 28 September 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been...
RESULTS OF COURT MEETING AND GENERAL MEETING
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT CONTAINS INSIDE...
Interim Results for the Six Months Ended 30 June 2021 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need
London, 24 September 2021 – Tiziana Life Sciences plc (“Tiziana”, LSE: TILS, NASDAQ: TLSA), a biotechnology company a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for...
Change of Registered Office
London/New York, 7 September 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announces that with immediate effect its registered...
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
NEW YORK and LONDON, September 7, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and...
Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings
London/New York, 3 September 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it had formally...
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio Durham, N.C., New York, N.Y. and London, September 2, 2021 – Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage...
Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ
London/New York, August 20, 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces that it has formally commenced its...
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil
Nasally administered Foralumab, once a day for 10 consecutive days, was well-tolerated and produced significant reduction in lung inflammation as assessed by computerized tomography (CT) scanning This anti-inflammatory effect of treatment was strongly supported by a...
ADS Ex-Dividend Date Scheduled for July, 09 2021
ADS Ex-Dividend Date Scheduled for July, 09 2021 THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY New York, 8 July 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology,...
Distribution Dates for shares and ADRs in Accustem Sciences Limited
London, New York, 2 July 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the Forms 20-F and...
Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today
NEW YORK & LONDON, June 30, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces an interview with the Chairman of its’ Scientific...
Result of Annual General Meeting
Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed. The results of the proxy voting will be available shortly on the...
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
NEW YORK & LONDON, June 23, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has...
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
NEW YORK & LONDON, June 21, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment of Dr. Kevin...
Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease
NEW YORK & LONDON, June 17, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases announces that it has submitted a grant to the United...
Posting of Notice of Annual General Meeting
For immediate release 2 June 2021 The Company announces that a letter to Shareholders has been posted advising that the Notice of Annual General Meeting has been made available on the Company’s website:...